Literature DB >> 31190108

[Immunosuppressive treatment and bone healing].

Dagmar Horn1, Christoph Klaas1, Michael Raschke2, Richard Stange3.   

Abstract

Due to demographic changes in the population and the development of novel immunosuppressive agents, an increasing number of trauma and orthopedic patients are taking concomitant immunosuppressive medication. These drugs might interfere with the healing process and can possibly retard or prevent wound and fracture healing and lead to a higher risk of infections. In these complex situations a structured and interdisciplinary process during hospital admission should preoperatively evaluate the possibility of interrupting immunosuppressive medications for the perioperative treatment period without risking a relapse of the underlying disease and which surgical approach should be individually selected for the patient.

Entities:  

Keywords:  Autoimmune diseases; Fracture healing; Immunosuppressive agents; Perioperative care; Transplantation

Mesh:

Substances:

Year:  2019        PMID: 31190108     DOI: 10.1007/s00113-019-0685-x

Source DB:  PubMed          Journal:  Unfallchirurg        ISSN: 0177-5537            Impact factor:   1.000


  20 in total

1.  Immunosuppression with FK506 has no influence on fracture healing in the rat.

Authors:  Gregor Voggenreiter; Patrizia Siozos; Eva Hunkemöller; Stefan Heute; Markus Schwarz; Udo Obertacke
Journal:  Bone       Date:  2005-08       Impact factor: 4.398

2.  [Recommendations of the German Society for Rheumatology on the perioperative approach under therapy with DMARDs and biologicals in inflammatory rheumatic diseases].

Authors:  K Krüger; K Albrecht; S Rehart; R Scholz
Journal:  Z Rheumatol       Date:  2014-02       Impact factor: 1.372

Review 3.  Update on medications with adverse skeletal effects.

Authors:  Caroline J Davidge Pitts; Ann E Kearns
Journal:  Mayo Clin Proc       Date:  2011-03-09       Impact factor: 7.616

4.  Prevalence of oral glucocorticoid usage in the United States: a general population perspective.

Authors:  Robert A Overman; Jun-Yen Yeh; Chad L Deal
Journal:  Arthritis Care Res (Hoboken)       Date:  2013-02       Impact factor: 4.794

5.  Effects of cyclosporin A on alveolar bone: an experimental study in the rat.

Authors:  E Fu; Y D Hsieh; S Nieh; U M Wikesjö; D Liu
Journal:  J Periodontol       Date:  1999-02       Impact factor: 6.993

6.  Bone non-union after osteotomy in patients treated with methotrexate.

Authors:  J C Gerster; R Bossy; J Dudler
Journal:  J Rheumatol       Date:  1999-12       Impact factor: 4.666

7.  Influence of cyclosporin A therapy on bone healing around titanium implants: a histometric and biomechanic study in rabbits.

Authors:  Celso E Sakakura; Rogério Margonar; Marinella Holzhausen; Francisco H Nociti; Rodolfo Candia Alba; Elcio Marcantonio
Journal:  J Periodontol       Date:  2003-07       Impact factor: 6.993

8.  Impaired fracture healing in the absence of TNF-alpha signaling: the role of TNF-alpha in endochondral cartilage resorption.

Authors:  L C Gerstenfeld; T J Cho; T Kon; T Aizawa; A Tsay; J Fitch; G L Barnes; D T Graves; T A Einhorn
Journal:  J Bone Miner Res       Date:  2003-09       Impact factor: 6.741

9.  Etanercept does not impair healing in rat models of tendon or metaphyseal bone injury.

Authors:  Olof Sandberg; Pernilla Eliasson; Therese Andersson; Fredik Agholme; Per Aspenberg
Journal:  Acta Orthop       Date:  2012-05-23       Impact factor: 3.717

10.  The effect of newer anti-rheumatic drugs on osteogenic cell proliferation: an in-vitro study.

Authors:  Ajay Malviya; Jan Herman Kuiper; Nilesh Makwana; Patrick Laing; Brian Ashton
Journal:  J Orthop Surg Res       Date:  2009-05-26       Impact factor: 2.359

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.